AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have found a novel technique for improving the efficacy of an antipneumococcal vaccine.
"Immunization of mice with pneumococcal surface adhesin A (PsaA) emulsified in complete Freund's adjuvant (CFA) provides protection against systemic infection with Streptococcus pneumoniae," but CFA is not suitable for use with humans, explained Dennis O. Gor and colleagues at Case Western Reserve University in Cleveland.
Fusing PsaA genes with those coding for immunostimulatory cytokines produced a similar enhancement without the use of CFA although the resulting vaccine was still inferior to a version based on pneumococcal capsular polysaccharide, Gor and coauthors found.
The researchers developed a set of constructs combining PsaA gene sequences with those encoding murine interleukin-2 (mIL-2), mIL-4, or a peptide derived from mIL-1beta. E. coli strains were engineered to express these PsaA-cytokine constructs, they said.
Mice vaccinated with transgenic E. coli expressing the PsaA-mIL-4 construct were partially protected against virulent S. pneumoniae infection, study data showed. This vaccine produced results comparable with those seen after CFA-enhanced PsaA-based immunization.
However, two inoculations with pneumococcal capsular ...